WARRINGTON, Pa., Nov. 8, 2016 /PRNewswire/ -- Windtree
Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused
on developing aerosolized KL4 surfactant therapies for respiratory
diseases, today announced that Craig
Frasier, President and Chief Executive Officer, will present
at the Stifel 2016 Healthcare Conference at the Lotte New York
Palace Hotel in New York. The presentation is scheduled for
Tuesday, November 15, 2016 at
8:45 am ET.
A live audio webcast will be available via the events page of
the Windtree website at http://windtreetx.investorroom.com/events.
A replay of the presentation will be archived on the Windtree
website for 30 days for those unable to listen live.
About Windtree Therapeutics
Windtree Therapeutics,
Inc. is a clinical-stage biotechnology company focused on
developing novel surfactant therapies for respiratory diseases
and other potential applications. Windtree's proprietary technology
platform includes a synthetic, peptide-containing surfactant (KL4
surfactant) that is structurally similar to endogenous pulmonary
surfactant and novel drug-delivery technologies being developed to
enable noninvasive administration of aerosolized KL4
surfactant. Windtree is focused initially on improving the
management of respiratory distress syndrome (RDS) in premature
infants and believes that its proprietary technology may make it
possible, over time, to develop a pipeline of KL4 surfactant
product candidates to address a variety of respiratory diseases for
which there are few or no approved therapies.
For more information, please visit the Company's website at
www.windtreetx.com.
Logo - http://photos.prnewswire.com/prnh/20160415/356055LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/windtree-therapeutics-to-present-at-stifel-2016-healthcare-conference-300359351.html
SOURCE Windtree Therapeutics, Inc.